STOCKIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESUpdated 2026-04-19
Here’s whether Intellia Therapeutics, Inc (NTLA) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.38% over 10 days); strong 1-year return of +117.9%; 3-month momentum positive (+19.6%). Currently 47.1% off its 52-week high. Score: +6/7.
NTLA is in a confirmed uptrend, trading above both its 50-day ($13.20) and 200-day ($13.02) moving averages. An RSI of 69.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +117.9% compares to +35.1% for SPY (beat the market by 82.8%). The current 47.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $21,793 today
vs. S&P 500 (SPY) — same period beat market by 82.8%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($13.02)
✓Above 50-day MA ($13.20)
✓RSI(14) neutral zone (30–70) — currently 69.5
✓Positive return (+117.9%)
!Within 10% of period high (−47.1%)
Period Range $14.95
$6.73$28.25
RSI (14) 69.5
0 · OversoldOverbought · 100
Key Metrics
Price$14.95
Period Return+117.9%
Period High$28.25
Period Low$6.73
Drawdown−47.1%
MA-50$13.20
MA-200$13.02
RSI (14)69.5
Avg Volume (30d)3.2M
vs. SPYbeat by 82.8%
Return Rank#180 of 996
Trend Signals
Price is above the 200-day moving average ($13.02)